16.10.2025 12:21
Based on reports from internet sources, Mira Pharmaceuticals (MIRA) experienced a dramatic surge in its stock value, soaring by 70% in after-hours trading. This remarkable upswing was fueled by the release of compelling preclinical data.
According to research findings, Mira Pharmaceuticals' oral drug, Mira-55, exhibited superior performance compared to injected morphine in preclinical trials. Mira-55 demonstrated a notable ability to alleviate pain and diminish inflammation, surpassing the effects observed with morphine.
The research revealed that Mira-55 effectively restored pain thresholds to normal levels and mitigated swelling by acting through CB2 receptors. In contrast, morphine only achieved partial reduction in inflammation. This marijuana analog is non-psychotropic and is aimed at the $70 billion non-opioid pain market.
